Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and tolerability of the investigational drug EF-022 in the
treatment of adult patients with Recurrent Respiratory Papillomatosis (RRP). Patients will be
administered EF-022, either intramuscular or subcutaneous, for a period of 6 months.
Preliminary effect of the drug on the disease will be evaluated by following the number and
severity of the lesions in the respiratory tract and the effect on voice changes.